Submitted:
09 January 2024
Posted:
10 January 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.1.1. Sample size
2.1.2. Sampling Method
2.2. Instrument
2.3. Data Analysis
2.3.1. Reliability and Normality
2.3.2. Descriptive statistics and test of association
2.3.3. Quantile Analysis
2.3.3.1. Model Expression
3. Results
3.1. Reliability and Normality Test
3.2. Demographic Characteristics of Participants
3.3. Awareness of HPV Infection and Vaccine
3.4. Distribution of Participants' Responses to HPV infection knowledge questions
3.5. Scored 20-Item Knowledge scale about HPV infection.
3.6. Participants’ knowledge scores stratified by participants’ characteristics.
3.7. Multivariate analysis for predicting knowledge score.
4. Discussion
4.1. Normality and Reliability
4.2. Demographic Characteristics
4.3. Awareness of HPV Infection and Vaccine
4.4. Knowledge of HPV Infection
4.5. Factors Associated with HPV Knowledge
5. Conclusion
6. Recommendations
7. Limitations
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
References
- M. Omone and M. Kozlovszky, “HPV and Cervical Cancer Screening Awareness: A Case-control Study in Nigeria,” in 2020 IEEE 24th International Conference on Intelligent Engineering Systems (INES), Jul. 2020, pp. 145–152. [CrossRef]
- “Cervical cancer.” Accessed: Feb. 26, 2020. [Online]. Available: https://www.who.int/healthtopics/cervical-cancer#tab=tab_1.
- Y. Husain, A. Y. Husain, A. Alalwan, Z. Al-Musawi, G. Abdulla, K. Hasan, and G. Jassim, “Knowledge towards human papilloma virus (HPV) infection and attitude towards its vaccine in the Kingdom of Bahrain: cross-sectional study,” BMJ Open, vol. 9, no. 9, p. e031017, Sep. 2019. [CrossRef]
- Pal and, R. Kundu, “Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy,” Front Microbiol, vol. 10, p. 3116, Jan. 2020. [CrossRef]
- S. L. Ranjeva et al., “Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity,” Proc Natl Acad Sci U S A, vol. 114, no. 51, pp. 13573–13578, Dec. 2017. [CrossRef]
- S. Collins, T. P. S. Collins, T. P. Rollason, L. S. Young, and C. B. J. Woodman, “Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study,” Eur J Cancer, vol. 46, no. 2, pp. 405–411, Jan. 2010. [CrossRef]
- B. Su et al., “The relation of passive smoking with cervical cancer,” Medicine (Baltimore), vol. 97, no. 46, p. e13061, Nov. 2018. [CrossRef]
- C. Chelimo, T. A. C. Chelimo, T. A. Wouldes, L. D. Cameron, and J. M. Elwood, “Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer,” J Infect, vol. 66, no. 3, pp. 207–217, Mar. 2013. [CrossRef]
- Cassa Macedo, A. Oliveira Vilela de Faria, and P. Ghezzi, “Boosting the Immune System, From Science to Myth: Analysis the Infosphere With Google,” Front Med (Lausanne), vol. 6, p. 165, Jul. 2019. [CrossRef]
- J. A. Fonseca-Moutinho, “Smoking and Cervical Cancer,” ISRN Obstet Gynecol, vol. 2011, 2011. [CrossRef]
- E. Mazarico and E. Gonzalez-Bosquet, “Prevalence of infection by different genotypes of human papillomavirus in women with cervical pathology,” Gynecol Oncol, vol. 125, no. 1, pp. 181–185, Apr. 2012. [CrossRef]
- O. Morhason-Bello et al., “Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women,” Infect Agent Cancer, vol. 16, no. 1, p. 59, Sep. 2021. [CrossRef]
- Y. Huang, X. Y. Huang, X. Wu, Y. Lin, W. Li, J. Liu, and B. Song, “Multiple sexual partners and vaginal microecological disorder are associated with HPV infection and cervical carcinoma development,” Oncol Lett, vol. 20, no. 2, pp. 1915–1921, Aug. 2020. [CrossRef]
- O. Morhason-Bello, Y. O. O. Morhason-Bello, Y. O. Kareem, and I. F. Adewole, “Modeling for Predictors of Knowledge Score on Etiology and Prevention Strategies for Cervical Cancer Among Women of Reproductive Age in Ibadan,” JCO Glob Oncol, vol. 6, p. GO.20.00086, Jun. 2020. [CrossRef]
- S. Okunade, C. M. S. Okunade, C. M. Nwogu, A. A. Oluwole, and R. I. Anorlu, “Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the out-patient clinics of a university teaching hospital in Lagos, Nigeria,” Pan Afr Med J, vol. 28, p. 227, Nov. 2017. [CrossRef]
- S. OKUNADE, “Human Papillomavirus and Cervical Cancer,” J Obstet Gynaecol, vol. 40, no. 5, pp. 602–608, Jul. 2020. [CrossRef]
- F. Carew, “Knowledge, Risk Factors And Perception Regarding Cervical Cancer Among Female Senior Secondary School Students In Minna, North Central Zone, Nigeria,” Jan. 2019, Accessed: Sep. 16, 2023. [Online]. Available: https://www.academia.edu/71544255/Knowledge_Risk_Factors_And_Perception_Regarding_Cervical_Cancer_Among_Female_Senior_Secondary_School_Students_In_Minna_North_Central_Zone_Nigeria. 7154.
- G. J. Gana, M. O. G. J. Gana, M. O. Oche, J. T. Ango, A. U. Kaoje, K. J. Awosan, and I. A. Raji, “Educational intervention on knowledge of cervical cancer and uptake of Pap smear test among market women in Niger State, Nigeria,” Journal of Public Health in Africa, vol. 8, no. 2, Art. no. 2, Dec. 2017. [CrossRef]
- A. Okunowo et al., “Women’s knowledge of cervical cancer and uptake of Pap smear testing and the factors influencing it in a Nigerian tertiary hospital,” Journal of Cancer Research and Practice, vol. 5, no. 3, pp. 105–111, Sep. 2018. [CrossRef]
- “Law in Nigeria - DLA Piper Global Data Protection Laws of the World.” Accessed: Aug. 08, 2022. [Online]. Available: https://www.dlapiperdataprotection.com/index.html?t=law&c=NG.
- Waller, R. Ostini, L. A. V. Marlow, K. McCaffery, and G. Zimet, “Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory,” Prev Med, vol. 56, no. 1, pp. 35–40, Jan. 2013. [CrossRef]
- B. Haward et al., “Development and validation of the cervical cancer knowledge scale and HPV testing knowledge scale in a sample of Canadian women,” Prev Med Rep, vol. 30, p. 102017, Oct. 2022. [CrossRef]
- S. Yarmohammadi, M. S. Yarmohammadi, M. Ghaffari, Y. Mehrabi, S. Mousavi, and A. Ramezankhani, “Designing and psychometric assessment of the scale of factors influencing HPV vaccine uptake behaviors in young adults,” Infectious Agents and Cancer, vol. 17, no. 1, p. 48, Sep. 2022. [CrossRef]
- Y. M. Larebo et al., “Awareness, Acceptance, and Associated Factors of Human Papillomavirus Vaccine among Parents of Daughters in Hadiya Zone, Southern Ethiopia: A Cross-Sectional Study,” Vaccines, vol. 10, no. 12, Art. no. 12, Dec. 2022. [CrossRef]
- T. Ararsa, N. Tadele, Y. Ayalew, and D. Gela, “Knowledge towards cervical cancer screening and associated factors among urban health extension workers at Addis Ababa, Ethiopia: facility based cross-sectional survey,” BMC Cancer, vol. 21, no. 1, p. 224, Mar. 2021. [CrossRef]
- N. Mofolo et al., “Knowledge of cervical cancer, human papillomavirus and prevention among first-year female students in residences at the University of the Free State,” Afr J Prim Health Care Fam Med, vol. 10, no. 1, p. 1637, 18. 20 May. [CrossRef]
- “Advanced multiprocessing capabilities.” Accessed: Sep. 16, 2023. [Online]. Available: https://www.stata.com/statamp/.
- M. Omone, A. U. Gbenimachor, L. Kovács, and M. Kozlovszky, “Knowledge Estimation with HPV and Cervical Cancer Risk Factors Using Logistic Regression,” in 2021 IEEE 15th International Symposium on Applied Computational Intelligence and Informatics (SACI), May 2021, pp. 000381–000386. [CrossRef]
- Schneider, G. Hommel, and M. Blettner, “Linear Regression Analysis,” Deutsches Ärzteblatt international, Nov. 2010. [CrossRef]
- Heo, N. Kim, and M. S. Faith, “Statistical power as a function of Cronbach alpha of instrument survey items,” BMC Medical Research Methodology, vol. 15, no. 1, p. 86, Oct. 2015. [CrossRef]
- Rochon, M. Gondan, and M. Kieser, “To test or not to test: Preliminary assessment of normality when comparing two independent samples,” BMC Medical Research Methodology, vol. 12, no. 1, p. 81, Jun. 2012. [CrossRef]
- S. Manikandan, “Measures of central tendency: The mean,” J Pharmacol Pharmacother, vol. 2, no. 2, pp. 140–142, Apr. 2011. [CrossRef]
- P. Z. Raçi, F. P. Z. Raçi, F. Raçi, and T. Hadri, “Kosovo women’s knowledge and awareness of human papillomavirus (HPV) infection, HPV vaccination, and its relation to cervical cancer,” BMC Women’s Health, vol. 21, no. 1, p. 354, Oct. 2021. [CrossRef]
- A. Wilson et al., “Newcomer knowledge, attitudes, and beliefs about human papillomavirus (HPV) vaccination,” BMC Family Practice, vol. 22, no. 1, p. 17, Jan. 2021. [CrossRef]
- C. L. Schwendener et al., “HPV vaccine awareness, knowledge and information sources among youth in Switzerland: a mixed methods study,” BMJ Open, vol. 12, no. 1, p. e054419, Jan. 2022. [CrossRef]
- D. Addisu, N. A. D. Addisu, N. A. Gebeyehu, and Y. Y. Belachew, “Knowledge, attitude, and uptake of human papillomavirus vaccine among adolescent schoolgirls in Ethiopia: a systematic review and meta-analysis,” BMC Women’s Health, vol. 23, no. 1, p. 279, 23. 20 May. [CrossRef]
- R. Anorlu, M. R. Anorlu, M. Adegbesan, and T. Adaramewa, “Knowledge of HPV and cervical cancer among HIV-positive women in Lagos, Nigeria,” Infectious Agents and Cancer, vol. 5, no. 1, p. A46, Oct. 2010. [CrossRef]
- C. Varer Akpinar and S. Alanya Tosun, “Knowledge and perceptions regarding Human Papillomavirus (HPV) and willingness to receive HPV vaccination among university students in a north-eastern city in Turkey,” BMC Women’s Health, vol. 23, no. 1, p. 299, Jun. 2023. [CrossRef]
- J. He and L. He, “Knowledge of HPV and acceptability of HPV vaccine among women in western China: a cross-sectional survey,” BMC Women’s Health, vol. 18, no. 1, p. 130, Jul. 2018. [CrossRef]
- C. D. Walsh, A. C. D. Walsh, A. Gera, M. Shah, A. Sharma, J. E. Powell, and S. Wilson, “Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination,” BMC Public Health, vol. 8, p. 368, Oct. 2008. [CrossRef]
- C. C. Ragin et al., “Knowledge about human papillomavirus and the HPV vaccine – a survey of the general population,” Infectious Agents and Cancer, vol. 4, no. 1, p. S10, Feb. 2009. [CrossRef]
| Statistics | Value |
|---|---|
| Cronbach's Alpha | 0.913 |
| Cronbach's Alpha Based on Standardized Items | 0.913 |
| Number of items | 20 |
| Variable | N | Z | P>z |
|---|---|---|---|
| Age | 304 | 7.22 | 0.000 |
| Characteristics | n (%) | Median (25–75 p) |
|---|---|---|
| Total | 304 (100) | |
| Variables | ||
| Age | 28 (24–35) | |
| Sex | ||
| Female | 135 (44.4) | |
| Male | 169 (55.6) | |
| Highest level of Educational | ||
| High School/Secondary Education | 18 (5.9) | |
| Tertiary Education (Bachelor’s degree) | 231 (76.0) | |
| Post Tertiary (Master’s degree/Doctorate) | 55 (18.1) | |
| Employment Status | ||
| Employed | 107 (35.2) | |
| Self-Employed | 89 (29.3) | |
| Unemployed | 108 (35.5) | |
| Marital Status | ||
| Divorced | 1 (0.3) | |
| Living with Partner | 7 (2.3) | |
| Married | 113 (37.2) | |
| Separated | 2 (0.7) | |
| Single | 177 (58.2) | |
| Widowed | 4 (1.3) | |
| Ethnicity | ||
| Hausa | 53 (17.4) | |
| Igbo | 28 (9.2) | |
| Yoruba | 66 (21.7) | |
| Other | 157 (51.6) | |
| Ever had sexual intercourse | ||
| Yes | 195 (66.1) | |
| No | 109 (35.9) | |
| Protected Sex | ||
| Yes | 100 (51.3) | |
| No | 95 (48.7) | |
| Kind of sex mostly engaged in | ||
| Anal, Oral, and Vaginal Sex | 16 (8.2) | |
| Vaginal sex only | 179 (91.8) |
| Variable | Yes n (%) | No n(%) |
|---|---|---|
| Awareness of HPV infection | ||
| Heard about HPV Infection? | 98 (34.8) | 206 (67.8) |
| Sources of information (multiple options) | ||
| Hospitals through doctors or nurses, or healthcare providers | 48 (15.8) | 256 (84.2) |
| Public health brochures, pamphlets, flyers or posters | 41 (13.5) | 263 (86.5) |
| Self-search on the internet | 43 (14.1) | 261 (85.9) |
| Social media through Facebook or Twitter e.t.c | 35 (11.5) | 269 (88.5) |
| Family member(s) or friend(s) or peer(s) | 24 (7.9) | 280 (92.1) |
| Tv or radio, newspapers or magazine | 9 (3.0) | 295 (97.0) |
| HPV Vaccine Information | ||
| Heard of HPV Vaccine? | 76 (25.0) | 228 (75.0) |
| Sources of information (multiple options) | ||
| Hospital through Doctors or nurses, or other health care provider(s) | 32 (10.6) | 272 (89.4) |
| Public health brochures, pamphlets, flyers, posters, etc | 35 (11.6) | 269 (88.5) |
| Self-search on the internet | 19 (6.3) | 285 (93.7) |
| Social media through Facebook or Instagram or Twitter, etc | 21 (6.9) | 283 (93.1) |
| Family member(s) or Friend(s) or peer or colleague | 22 (7.3) | 281 (92.7) |
| TV or radio, Newspapers or magazines | 6 (2.0) | 298 (98.0) |
| Have you taken the Vaccine | 10 (3.3) | 294 (96.7) |
| Knowledge Statements | Strongly Agree | Agree | Neutral | Disagree | Strongly Disagree | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| HPV was a virus, not a bacteria | 65 | 54.2 | 36 | 30.0 | 6 | 5.0 | 3 | 2.5 | 10 | 8.3 |
| Women cannot contract HPV infection | 1 | 0.8 | 5 | 4.2 | 2 | 1.7 | 33 | 27.5 | 79 | 65.8 |
| Men cannot contract HPV infection | 3 | 2.5 | 9 | 7.5 | 10 | 8.3 | 37 | 30.8 | 61 | 50.8 |
| In most cases, HPV infection may not cause any symptoms | 19 | 15.8 | 35 | 29.2 | 31 | 25.8 | 22 | 18.3 | 13 | 10.8 |
| HPV 16 and 18 Genotypes are High-risk HPV Genotypes | 21 | 17.5 | 25 | 20.8 | 65 | 54.2 | 4 | 3.3 | 5 | 4.2 |
| HPV 6, 11, 42 and 61 Genotypes are High-risk HPV Genotypes | 11 | 9.2 | 22 | 18.3 | 77 | 64.2 | 9 | 7.5 | 1 | 0.8 |
| Having sex at an early age increases the risk of getting HPV infection | 36 | 30.0 | 43 | 35.8 | 21 | 17.5 | 17 | 14.2 | 3 | 2.5 |
| HPV infection usually doesn’t need any treatment to clear before it goes | 8 | 6.7 | 14 | 11.7 | 19 | 15.8 | 36 | 30.0 | 43 | 35.8 |
| HPV can be contracted through sexual intercourse | 53 | 44.2 | 51 | 42.5 | 6 | 5.0 | 1 | 0.8 | 9 | 7.5 |
| HPV-related genital warts are cancerous | 17 | 14.2 | 45 | 37.5 | 34 | 28.3 | 14 | 11.7 | 10 | 8.3 |
| There are several types of HPV Genotypes (e.g. 6, 11, 16, 18, 70, 72) | 28 | 23.3 | 32 | 26.7 | 54 | 45.0 | 5 | 4.2 | 1 | 0.8 |
| HPV 16 and 18 infections can lead to cervical cancer if untreated for a long time. | 27 | 27.6 | 44 | 44.9 | 23 | 23.5 | 2 | 2.0 | 2 | 2.0 |
| HPV infection can be contracted from an infected person through genital skin. | 30 | 25.0 | 49 | 40.8 | 22 | 18.3 | 12 | 10.0 | 7 | 5.8 |
| Some HPV genotype infections can cause genital warts. | 31 | 25.8 | 57 | 47.5 | 25 | 20.8 | 5 | 4.2 | 2 | 1.7 |
| HPV infection can cause HIV/AIDS infections | 11 | 9.2 | 19 | 15.8 | 33 | 27.5 | 30 | 25.0 | 27 | 22.5 |
| Having multiple sexual partners increases the risk of contracting HPV infection. | 44 | 44.9 | 41 | 41.8 | 5 | 5.1 | 3 | 3.1 | 5 | 5.1 |
| HPV infection can be cured with Antibiotics. | 7 | 5.83 | 34 | 28.33 | 40 | 33.33 | 15 | 12.50 | 3 | 2.50 |
| The use of condoms reduces the risk of HPV infection. | 42 | 35.00 | 54 | 45.00 | 15 | 12.50 | 6 | 5.00 | 3 | 2.50 |
| A person could be HPV infected for several years and not know it. | 29 | 24.17 | 69 | 57.50 | 11 | 9.17 | 8 | 6.67 | 3 | 2.50 |
| Most sexually active people will get HPV infection at some point in their lifetime. | 17 | 14.17 | 31 | 25.83 | 38 | 31.67 | 25 | 20.83 | 9 | 7.50 |
| Knowledge Statement | Correct | Wrong | ||
|---|---|---|---|---|
| N | % | N | % | |
| HPV was a virus, not a bacterium. | 36 | 11.8 | 268 | 88.2 |
| Women cannot contract HPV infection. | 79 | 26.0 | 225 | 74.0 |
| Men cannot contract HPV infection. | 61 | 20.1 | 243 | 79.9 |
| In most cases, HPV infection may not cause any symptoms. | 19 | 6.3 | 285 | 93.7 |
| HPV 16 and 18 Genotypes are High-risk HPV Genotypes. | 21 | 6.9 | 283 | 93.1 |
| HPV 6, 11, 42 and 61 Genotypes are High-risk HPV Genotypes. | 11 | 3.6 | 293 | 96.4 |
| Having sex at an early age increases the risk of getting HPV infection. | 36 | 11.8 | 268 | 88.2 |
| HPV infection usually doesn’t need any treatment to clear before it goes. | 8 | 2.6 | 296 | 97.4 |
| HPV can be contracted through sexual intercourse. | 53 | 17.4 | 251 | 82.6 |
| HPV-related genital warts are cancerous. | 10 | 3.3 | 294 | 96.7 |
| There are several types of HPV Genotypes (e.g. 6, 11, 16, 18, 70, 72). | 28 | 9.2 | 276 | 90.8 |
| HPV 16 and 18 infections can lead to cervical cancer if untreated for a long time. | 27 | 8.9 | 277 | 91.1 |
| HPV infection can be contracted from an infected person through genital skin. | 30 | 9.9 | 274 | 90.1 |
| Some HPV genotype infections can cause genital warts. | 31 | 10.2 | 273 | 89.8 |
| HPV infection can cause HIV/AIDS infections. | 27 | 8.9 | 277 | 91.1 |
| Having multiple sexual partners increases the risk of contracting HPV infection. | 44 | 14.5 | 260 | 85.5 |
| HPV infection can be cured with Antibiotics. | 24 | 7.9 | 280 | 92.1 |
| The use of condoms reduces the risk of HPV infection. | 42 | 13.8 | 262 | 86.2 |
| A person could be HPV infected for several years and not know it. | 29 | 9.5 | 275 | 90.5 |
| Most sexually active people will get HPV infection at some point in their lifetime. | 17 | 5.6 | 287 | 94.4 |
| Characteristics | Knowledge Score | p-Value |
|---|---|---|
| Median (25–75 p) | ||
| Sex | 0.000 | |
| Female | 0 (0–6) | |
| Male | 0 (0–4) | |
| Highest level of Educational | ||
| High School/Secondary Education | 2.5 (0-6) | 0.000 |
| Tertiary Education (bachelor’s degree) | 5 (0-7) | |
| Post Tertiary (master’s degree/Doctorate) | 0 (0-4) | |
| Employment Status | ||
| Employed | 0 (0-6) | 0.401 |
| Self-Employed | 0 (0-5) | |
| Unemployed | 0 (0-5) | |
| Ever had sexual intercourse | ||
| Yes | 0 (0-6) | 0.073 |
| No | 0 (0-3) | |
| Protected Sex | ||
| Yes | 0 (0-6) | 0.461 |
| No | 0 (0-6) | |
| Ethnicity | ||
| Hausa | 0 (0-2) | 0.001 |
| Igbo | 5 (0-8) | |
| Yoruba | 0 (0-5) | |
| Other | 0 (0-4) |
| Characteristics | Coefficient | 95% C.I. Lower Limit | 95% C.I. Upper Limit | p-Value |
|---|---|---|---|---|
| Sex | ||||
| Male | -2.5 | -5.34 | 0.34 | 0.084 |
| Education | ||||
| Post Tertiary | 2.5 | -0.95 | 5.95 | 0.154 |
| Tertiary Education | -0.5 | -4.81 | 3.81 | 0.82 |
| Ethnic | ||||
| Igbo | 4.0 | 0.20 | 7.80 | 0.039 |
| Yoruba | 0.5 | -2.53 | 3.53 | 0.745 |
| Other | 2.0 | -1.29 | 5.29 | 0.232 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).